On March 10, 2025, Beam Therapeutics announced positive initial data from its Phase 1/2 trial of BEAM-302 for treating alpha-1 antitrypsin deficiency, showing well-tolerated treatment with significant increases in functional AAT levels. The trial involved 9 patients, with dose levels of 15 mg, 30 mg, and 60 mg, demonstrating a 1.6x to 2.8x increase in total AAT from baseline after treatment.